E Jenny Heathcote

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi request reprint Clinical trials in chronic liver disease - what do they achieve?
    Jenny Heathcote
    University Health Network, Toronto Western Hospital, Toronto, Canada
    Can J Gastroenterol 18:489-92. 2004
  2. pmc MAID : an effect size based model for microarray data integration across laboratories and platforms
    Ivan Borozan
    Banting and Best Department of Medical Research, University of Toronto, 112 College St, Toronto, ON M5G1L6, Canada
    BMC Bioinformatics 9:305. 2008
  3. pmc Weighty issues in hepatitis C
    J Heathcote
    Toronto Western Hospital, University Health Network, 399 Bathurst St, 6B Fell Pavilion, Room 172, Toronto, Ontario M5T 2S8, Canada
    Gut 51:7-8. 2002
  4. ncbi request reprint Prevention of hepatitis C virus-related hepatocellular carcinoma
    E Jenny Heathcote
    Toronto Western Hospital, 6B Fell 156, 399 Bathurst St, Toronto, ON M5T 2S8, Canada
    Gastroenterology 127:S294-302. 2004
  5. ncbi request reprint Treatment of HBe antigen-positive chronic hepatitis B
    Jenny Heathcote
    University of Toronto, Toronto Western Hospital, Ontario, Canada
    Semin Liver Dis 23:69-80. 2003
  6. ncbi request reprint Treatment of hepatitis B: the next five years
    E Jenny Heathcote
    University of Toronto, Ontario, Canada
    Clin Med 7:472-7. 2007
  7. ncbi request reprint Antiviral therapy: chronic hepatitis C
    E Jenny Heathcote
    University of Toronto, Toronto, ON, Canada
    J Viral Hepat 14:82-8. 2007
  8. ncbi request reprint Results of lamivudine therapy for HBe antigen positive hepatitis (in the West)
    Jenny Heathcote
    Toronto Western Hospital, University of Toronto, University Health Network 6B Fell Room 170, 399 Bathurst Street, Toronto, Ont M5T 2S8, Canada
    J Hepatol 39:S106-10. 2003
  9. ncbi request reprint Diagnosis and management of cholestatic liver disease
    E Jenny Heathcote
    University Health Network, University of Toronto, Hepatology, Toronto, Ontario, Canada
    Clin Gastroenterol Hepatol 5:776-82. 2007
  10. ncbi request reprint Primary biliary cirrhosis: historical perspective
    E Jenny Heathcote
    University of Toronto, Toronto, ON, 170 6B Fell, Toronto Western Hospital, 399 Bathurst St Toronto, ON M5T 2S8, Canada
    Clin Liver Dis 7:735-40. 2003

Detail Information

Publications110 found, 100 shown here

  1. ncbi request reprint Clinical trials in chronic liver disease - what do they achieve?
    Jenny Heathcote
    University Health Network, Toronto Western Hospital, Toronto, Canada
    Can J Gastroenterol 18:489-92. 2004
  2. pmc MAID : an effect size based model for microarray data integration across laboratories and platforms
    Ivan Borozan
    Banting and Best Department of Medical Research, University of Toronto, 112 College St, Toronto, ON M5G1L6, Canada
    BMC Bioinformatics 9:305. 2008
    ..The increase in sensitivity and reliability of measurements of gene expression changes can be improved through a systematic integration of different microarray datasets that address the same or similar biological questions...
  3. pmc Weighty issues in hepatitis C
    J Heathcote
    Toronto Western Hospital, University Health Network, 399 Bathurst St, 6B Fell Pavilion, Room 172, Toronto, Ontario M5T 2S8, Canada
    Gut 51:7-8. 2002
  4. ncbi request reprint Prevention of hepatitis C virus-related hepatocellular carcinoma
    E Jenny Heathcote
    Toronto Western Hospital, 6B Fell 156, 399 Bathurst St, Toronto, ON M5T 2S8, Canada
    Gastroenterology 127:S294-302. 2004
    ..Studies of maintenance peginterferon therapy in virological nonresponders are under way in the hope of proving that this approach is effective in decreasing the risk of HCC...
  5. ncbi request reprint Treatment of HBe antigen-positive chronic hepatitis B
    Jenny Heathcote
    University of Toronto, Toronto Western Hospital, Ontario, Canada
    Semin Liver Dis 23:69-80. 2003
    ..Both patient and physician need to recognize the need for close monitoring both during and after cessation of any antiviral therapy for hepatitis B...
  6. ncbi request reprint Treatment of hepatitis B: the next five years
    E Jenny Heathcote
    University of Toronto, Ontario, Canada
    Clin Med 7:472-7. 2007
    ..Drug resistance needs to be identified prior to recurrence of hepatitis (rise in ALT) to prevent hepatic decompensation, this necessitates serial HBV-DNA testing...
  7. ncbi request reprint Antiviral therapy: chronic hepatitis C
    E Jenny Heathcote
    University of Toronto, Toronto, ON, Canada
    J Viral Hepat 14:82-8. 2007
    ..Other immunomodulatory agents such as new IFN or therapeutic vaccines and alternatives to ribavirin are also under development. Future regimens should improve efficacy and provide shorter and better-tolerated combination therapy...
  8. ncbi request reprint Results of lamivudine therapy for HBe antigen positive hepatitis (in the West)
    Jenny Heathcote
    Toronto Western Hospital, University of Toronto, University Health Network 6B Fell Room 170, 399 Bathurst Street, Toronto, Ont M5T 2S8, Canada
    J Hepatol 39:S106-10. 2003
  9. ncbi request reprint Diagnosis and management of cholestatic liver disease
    E Jenny Heathcote
    University Health Network, University of Toronto, Hepatology, Toronto, Ontario, Canada
    Clin Gastroenterol Hepatol 5:776-82. 2007
    ..Ursodeoxycholic acid improves the biochemical markers of cholestasis regardless of cause and may delay liver disease progression; only liver transplant is potentially curative...
  10. ncbi request reprint Primary biliary cirrhosis: historical perspective
    E Jenny Heathcote
    University of Toronto, Toronto, ON, 170 6B Fell, Toronto Western Hospital, 399 Bathurst St Toronto, ON M5T 2S8, Canada
    Clin Liver Dis 7:735-40. 2003
    ..No specific therapy that effectively stops or reverses disease progression has been identified, thus it behoves investigators to aggressively pursue identification of the etiology of PBC...
  11. ncbi request reprint Treatment considerations in patients with hepatitis C and cirrhosis
    E Jenny Heathcote
    University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
    J Clin Gastroenterol 37:395-8. 2003
    ..Thus, individuals with any evidence of hepatic decompensation should generally not be given interferon-based antiviral therapy, but treatment should be encouraged for those whose status is Child Class A...
  12. ncbi request reprint Variant syndromes of autoimmune hepatitis
    Jenny Heathcote
    University Health Network, Toronto Western Hospital, 399 Bathurst Street, 6B 170 Fell Pavilion, Toronto, Ontario M5T 2S8, Canada
    Clin Liver Dis 6:669-84. 2002
    ..It is only after boundaries have been decided by consensus that the true variants of autoimmune liver disease can be appreciated. Until then, both the diagnosis and treatment of these syndromes will be arbitrary and unclear...
  13. doi request reprint Retreatment of chronic hepatitis C: who and how?
    Jenny Heathcote
    University of Toronto, Toronto, ON, Canada
    Liver Int 29:49-56. 2009
    ..Lifestyle modification may be appropriate in attempt to reduce the chance of complications of liver disease, namely hepatocellular carcinoma, by smoking cessation, eliminating obesity and increasing coffee consumption...
  14. doi request reprint Demography and presentation of chronic hepatitis B virus infection
    E Jenny Heathcote
    Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
    Am J Med 121:S3-11. 2008
    ..Targeted vaccination of high-risk groups has many limitations. Universal childhood vaccination to prevent chronic infection and its sequelae is the only approach that will lead to the global elimination of chronic HBV infection...
  15. ncbi request reprint When to treat patients with chronic hepatitis C
    Jenny Heathcote
    Department of Medicine, Toronto Western Hospital, University Health Network University of Toronto, 399 Bathurst Street, Fell Pavilion, 6th Floor, Room 170, Toronto, ON M5T 2S8, Canada
    Curr Gastroenterol Rep 6:261-3. 2004
  16. ncbi request reprint Pegylated interferon monotherapy for chronic hepatitis C
    Jenny Heathcote
    Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
    Semin Liver Dis 24:39-45. 2004
    ..0 microg/kg dose and achieved 25% compared with 12% in the standard IFN group. In conclusion, each regimen of pegylated IFN given once weekly is more effective than a regimen of standard IFN given three times weekly...
  17. doi request reprint Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection
    Limin Chen
    Banting and Best Department of Medical Research, University of Toronto, Toronto, Ontario, Canada
    Gastroenterology 138:1123-33.e1-3. 2010
    ..We here study how the nonresponder gene expression phenotype is influenced by clinical factors and uncover the cellular basis of the phenotype through ISG15 protein expression...
  18. doi request reprint Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype
    Ian McGilvray
    University Health Network, Toronto, Ontario, Canada
    Gastroenterology 142:1122-1131.e1. 2012
    ..It is not known how the IL28B genotype influences the ISG expression pattern and which is a better predictor of treatment response...
  19. pmc Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis
    Xiangdong Liu
    University Health Network, Toronto, Ontario, Canada
    Nat Genet 42:658-60. 2010
    ..9 x 10(-11), odds ratio (OR) = 1.46), IRF5-TNPO3 (P = 2.8 x 10(-10), OR = 1.63) and 17q12-21 (P = 1.7 x 10(-10), OR = 1.38)...
  20. ncbi request reprint Non-alcoholic fatty liver disease in HIV infection associated with altered hepatic fatty acid composition
    Bianca M Arendt
    University Health Network, Dept of Medicine, Toronto, Ontario, Canada
    Curr HIV Res 9:128-35. 2011
    ..Changes may be due to impaired FA metabolism or suboptimal n-3 PUFA intake. The potential role of n-3 PUFA (e.g. fish oil) to treat or prevent HIV/NAFLD warrants further investigation...
  21. doi request reprint Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis
    Teru Kumagi
    Liver Centre, Toronto Western Hospital, University Health Network, Ontario, Canada
    Am J Gastroenterol 105:2186-94. 2010
    ..We sought to develop clinically meaningful markers for those with predominantly early disease at risk of progressive liver damage...
  22. ncbi request reprint Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B
    Jordan J Feld
    Department of Medicine, University of Toronto, Toronto, Canada
    Hepatology 46:1057-70. 2007
    ..For HBeAg-negative patients with elevated ALT and all HBeAg-positive patients, HBV DNA did not predict future ALT. Other viral and host factors were not predictive of future ALT...
  23. pmc Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3
    J Powis
    Department of Medicine, University of Toronto, Toronto, ON, Canada
    J Viral Hepat 15:52-7. 2008
    ..027). There is significant interaction between cirrhosis and genotype 3 leading to a poor antiviral response in such patients requiring an alternate management strategy. This finding should be confirmed in a larger population...
  24. doi request reprint Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis
    Conor O'Brien
    Department of Medicine, University Health Network, Toronto Western Hospital, University of Toronto, Toronto, Canada
    Hepatology 48:550-6. 2008
    ....
  25. pmc Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis
    Gideon M Hirschfield
    Liver Centre, Toronto Western Hospital, Toronto, Ontario, Canada
    Nat Genet 42:655-7. 2010
    ..Fine-mapping studies showed that a single variant accounts for the IRF5-TNPO3 association. As these loci are implicated in other autoimmune conditions, these findings confirm genetic overlap among such diseases...
  26. doi request reprint Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses
    Gloria Woo
    Toronto Health Economics and Technology Assessment Collaborative, University of Toronto, Toronto, Ontario, Canada
    Gastroenterology 139:1218-29. 2010
    ..We evaluated the relative efficacies of the first 12 months of CHB treatments...
  27. doi request reprint ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment
    Limin Chen
    Banting and Best Department of Medical Research, University of Toronto, Toronto, Ontario, Canada
    J Gen Virol 91:382-8. 2010
    ..HCV might exploit ISG15 as a host immune evasion mechanism, and this may in part explain how increased expression of ISGs, especially ISG15, correlates with subsequent IFN-based treatment failure...
  28. ncbi request reprint High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C
    Brian L Bressler
    Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    Hepatology 38:639-44. 2003
    ..In conclusion, obesity, only when defined as a BMI greater than 30 kg/m(2), is an independent (of genotype and cirrhosis) negative predictor of response to hepatitis C treatment...
  29. ncbi request reprint Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C
    Sharif Missiha
    Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    Am J Gastroenterol 102:2181-8. 2007
    ..The lower response rate of African-Americans relative to whites has been previously described, but studies of other racial or ethnic groups remain limited...
  30. doi request reprint Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease
    Piotr Milkiewicz
    Department of Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Clin Gastroenterol Hepatol 7:1355-60. 2009
    ....
  31. doi request reprint CTLA4/ICOS gene variants and haplotypes are associated with rheumatoid arthritis and primary biliary cirrhosis in the Canadian population
    Erin J Walker
    University of Toronto, Toronto General Hospital, and Mount Sinai Hospital, Toronto, Ontario, Canada
    Arthritis Rheum 60:931-7. 2009
    ..We undertook this study to examine whether CTLA4 and ICOS influence RA and PBC susceptibility by testing CTLA4/ICOS polymorphisms for association with these diseases in Canadian subjects...
  32. doi request reprint Influence of hepatitis C virus on neurocognitive function in patients free from other risk factors: validation from therapeutic outcomes
    Venessa Pattullo
    Department of Medicine, University Health Network, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
    Liver Int 31:1028-38. 2011
    ..This longitudinal study aimed to quantify these abnormalities in a cohort of patients free from correlated risk factors and determine whether treatment-induced viral clearance abolished these abnormalities...
  33. ncbi request reprint Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection
    Limin Chen
    Banting and Best Department of Medical Research, University of Toronto, Ontario, Canada
    Gastroenterology 128:1437-44. 2005
    ..A large proportion of patients do not respond to therapy for reasons that are unclear. We used gene expression profiling to investigate the molecular basis for treatment failure...
  34. ncbi request reprint Early prediction of nonresponders to treatment with interferon alpha-2b and ribavirin in patients with chronic hepatitis C
    Louis W C Liu
    Department of Medicine, McMaster University, Hamilton, Ontario
    Can J Gastroenterol 17:483-7. 2003
    ..Furthermore, less than 50% of patients overall have a sustained virological response (SVR)...
  35. pmc Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin
    Morris Sherman
    Toronto General Hospital, University of Toronto, Toronto, Canada
    Can J Gastroenterol 20:479-85. 2006
    ....
  36. doi request reprint Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C
    Ava A John-Baptiste
    Department of Health Policy, Management and Evaluation, University of Toronto, Toronto General Hospital, EN13 239, 200 Elizabeth Street, Toronto, ON M5G 2C4, Canada
    Am J Gastroenterol 104:2439-48. 2009
    ..We sought to compare the health status of patients with a sustained response to antiviral therapy for hepatitis C virus (HCV) infection with that of treatment failures, using health-related quality of life and preference (utility) measures...
  37. ncbi request reprint High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C
    David N Moskovitz
    Department of Medicine, University of Toronto, Toronto, Ontario
    Can J Gastroenterol 17:479-82. 2003
    ..The purpose of the present study was to evaluate the efficacy of treatment with high dose consensus IFN (CIFN) (15 microg/day) in nonresponders...
  38. ncbi request reprint Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis?
    Supriya Joshi
    Department of Medicine, University Health Network, University of Toronto, Ontario, Canada
    Am J Gastroenterol 97:999-1002. 2002
    ..We aimed to confirm whether AMA profiles predict prognosis in a large sample of North American patients with PBC...
  39. ncbi request reprint Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus
    Nazira Chatur
    Department of Medicine, University of British Columbia, Vancouver, BC, Canada
    Liver Int 25:723-7. 2005
    ..Novel drug treatments include immunosuppressive drugs such as tacrolimus (TAC), mycophenolate mofetil (MMF), methotrexate and cyclosporine. We describe a multi-centre Canadian experience with MMF and TAC...
  40. pmc Sociocultural factors that potentially affect the institution of prevention and treatment strategies for prevention of hepatitis B in Chinese Canadians
    Harry Wu
    University of Toronto, Toronto, Ontario, Canada
    Can J Gastroenterol 23:31-6. 2009
    ..Despite the availability of screening for chronic hepatitis B (CHB) infection and effective treatments now available, many at-risk individuals fail to seek appropriate medical attention...
  41. ncbi request reprint Diffuse skin reaction in patient with hepatitis B, treated with two different formulations of pegylated interferon
    Piotr Milkiewicz
    Toronto Western Hospital, University Health Network, Toronto, Ontario
    Can J Gastroenterol 19:677-8. 2005
    ..This is important, because discontinuation of PegINF may decrease the chance of achieving a sustained virological response in patients with viral hepatitis...
  42. pmc Primary biliary cirrhosis
    Teru Kumagi
    Department of Medicine, Toronto Western Hospital University Health Network University of Toronto, Toronto, Ontario, Canada
    Orphanet J Rare Dis 3:1. 2008
    ..Recently, animal models have been discovered that may provide a new insight into the pathogenesis of this disease and facilitate appreciation for novel treatment in PBC...
  43. ncbi request reprint Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid
    Supriya Joshi
    Department of Medicine, The University Health Network, University of Toronto, Toronto, Ontario, Canada
    Hepatology 35:409-13. 2002
    ..Survival was similar for patients with PBC with and without ANA. In conclusion, features of AIH in PBC may be transient and response to UDCA therapy similar to patients with PBC without features of AIH...
  44. doi request reprint Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B
    E Jenny Heathcote
    University of Toronto, Toronto, Ontario, Canada
    Gastroenterology 140:132-43. 2011
    ..We evaluated long-term efficacy and safety of TDF monotherapy in patients with chronic hepatitis B who were positive or negative for hepatitis B e antigen (HBeAg(+) or HBeAg(-))...
  45. doi request reprint Pathogenesis of cholestatic liver disease and therapeutic approaches
    Gideon M Hirschfield
    Liver Centre, Toronto Western Hospital, Toronto, Ontario, Canada
    Gastroenterology 139:1481-96. 2010
    ..These discoveries will hopefully lead to new therapeutic approaches for patients with cholestatic liver disease...
  46. doi request reprint The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression
    Ava John-Baptiste
    Department of Health Policy, Management and Evaluation, University of Toronto, Canada
    J Hepatol 53:245-51. 2010
    ..Our aim was to estimate the rate of progression to cirrhosis for those infected with hepatitis C virus (HCV) through injection drug use...
  47. ncbi request reprint Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990
    Murray Krahn
    Toronto General Hospital, ES9 408, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada
    Med Decis Making 24:20-9. 2004
    ..To develop a natural history model for chronic hepatitis C virus (HCV) infection to determine allocation of compensatory funds to Canadians who acquired HCV through the blood supply from 1986 through 1990...
  48. ncbi request reprint Pancreatic pseudotumor with sclerosing pancreato-cholangitis: is this a systemic disease?
    Mohssen Nassiri Toosi
    Department of Medicine, University Health Network, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
    Am J Gastroenterol 99:377-82. 2004
    ..A review of the presenting features of all patients given a diagnosis of PSC at a single center was conducted. The aim was to clarify the presentation of patients with pseudotumor of the pancreas in this patient population...
  49. doi request reprint Preventative hepatology: minimising symptoms and optimising care
    Gideon M Hirschfield
    Toronto Western Hospital, University Health Network, University of Toronto, ON, Canada
    Liver Int 28:922-34. 2008
    ....
  50. ncbi request reprint Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome
    Jordan J Feld
    Department of Medicine and Pathology, University Health Network, University of Toronto, Canada
    Hepatology 42:53-62. 2005
    ..In conclusion, patients with AIH who are asymptomatic at presentation have a good prognosis and may not require immunosuppressive therapy. Cirrhosis on initial liver biopsy portends a poor prognosis in all patients with AIH...
  51. doi request reprint Prevalence and predictors of obesity among individuals with positive hepatitis C antibody in a tertiary referral clinic
    Wendong Chen
    Department of Health Policy, Management and Evaluation, University of Toronto, Toronto Western Hospital, Toronto, Ont, Canada M5T 2S8
    J Hepatol 49:711-7. 2008
    ..To determine the prevalence of obesity and investigate factors associated with obesity in a hepatitis C antibody positive clinic population...
  52. doi request reprint Hepatitis C and diabetes: one treatment for two diseases?
    Venessa Pattullo
    Division of Gastroenterology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, ON, Canada
    Liver Int 30:356-64. 2010
    ..morbidity and mortality by preventing or treating diabetes? Can we improve the response to antiviral therapy by pretreating IR and T2DM in treatment candidates? Ultimately, can we cure two diseases, diabetes and CHC, with one treatment?..
  53. doi request reprint Endpoints of therapy in chronic hepatitis B
    Jordan J Feld
    From the Toronto Western Hospital Liver Centre, Department of Medicine, Division of Gastroenterology, University of Toronto, Toronto, Canada
    Hepatology 49:S96-S102. 2009
    ..Future research should be directed at development and validation of surrogate markers that accurately predict or reflect clinically relevant outcomes of chronic hepatitis B...
  54. ncbi request reprint A Canadian multicenter retrospective study evaluating transjugular liver biopsy in patients with congenital bleeding disorders and hepatitis C: is it safe and useful?
    Jennifer L Shin
    Department of Medicine at University Health Network, University of Toronto, Toronto, Ontario, Canada
    Am J Hematol 78:85-93. 2005
    ..We conclude that this procedure can be safely performed on an outpatient basis. The diagnosis of cirrhosis and/or portal hypertension was made in a substantial proportion of individuals (26%), all of whom had asymptomatic liver disease...
  55. pmc Hepatitis B learning needs assessment of family medicine trainees in Canada: results of a nationwide survey
    Justina Joyce Sam
    Department of Medicine, University of Toronto, Toronto, Ontario
    Can J Gastroenterol 25:127-34. 2011
    ..An estimated 350 million people worldwide have chronic hepatitis B (CHB), which is a major cause of cirrhosis and hepatocellular carcinoma...
  56. ncbi request reprint Symptomatic and virological response to antiviral therapy in hepatitis C associated with extrahepatic complications of cryoglobulimia
    Supriya Joshi
    Department of Medicine, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, Ontario M5T 2S8, USA
    Dig Dis Sci 52:2410-7. 2007
    ..Treatment provided sustained symptomatic response in 31 (82%) and virological response in 16 (42%) patients. Symptomatic cryoglobulinemia responds well to antiviral therapy, even when virological response is not achieved...
  57. doi request reprint Hepatic fatty acid composition differs between chronic hepatitis C patients with and without steatosis
    Bianca M Arendt
    University Health Network, Department of Medicine, Toronto, M5G 2C4 Ontario, Canada
    J Nutr 139:691-5. 2009
    ..Oxidative stress or nutritional status does not seem to play a predominant role for development of steatosis in CHC...
  58. doi request reprint Impact of cirrhosis and liver transplant on maternal health during labor and delivery
    Sanjay K Murthy
    Division of Gastroenterology, Mount Sinai Hospital, University of Toronto, Toronto, Canada
    Clin Gastroenterol Hepatol 7:1367-72, 1372.e1. 2009
    ..The impact of cirrhosis or prior liver transplant on maternal health during pregnancy has not been studied. We sought to characterize outcomes during labor and delivery among pregnant women with these 2 conditions...
  59. doi request reprint Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging
    Rupert Abdalian
    Department of Medicine, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
    Hepatology 47:949-57. 2008
    ..Our data suggest that routine radiological evaluation of the biliary tree should be performed in adults given a diagnosis of AIH, as in children the presence of this overlap negatively impacts on survival...
  60. ncbi request reprint Abnormal intestinal permeability in primary biliary cirrhosis
    Jordan J Feld
    Division of Gastroenterology, University of Toronto, Toronto, Ontario, Canada
    Dig Dis Sci 51:1607-13. 2006
    ..016+/-0.011) (P=NS). We conclude that the permeability of both the stomach and the small bowel is increased in patients with PBC, however, it is unclear if it is a cause, consequence, or manifestation of the disease...
  61. ncbi request reprint Apoptosis of biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis
    Jill Tinmouth
    Department of Medicine, University Health Network, Toronto, Ontario, Canada
    Liver 22:228-34. 2002
    ..In this study, apoptosis and portal triad inflammation in liver tissue from patients with PBC is examined and compared to that from patients with PSC and patients with normal liver...
  62. pmc Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients
    Maciej Witkos
    Department of Health Policy, Management and Evaluation, University of Toronto, Toronto General Hospital, Ontario, Canada
    Can J Gastroenterol 20:107-11. 2006
    ..The efficacy of therapy has recently improved with the addition of ribavirin and pegylated interferon. The aim of the present study was to identify the clinical, socioeconomic and health-system predictors of antiviral treatment for HCV...
  63. doi request reprint Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors
    Sharif B Missiha
    Division of Gastroenterology, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Gastroenterology 134:1699-714. 2008
    ..Unfortunately, to date, there are no reliable predictive models that can accurately estimate the risk of CHC disease progression...
  64. pmc Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants
    Gideon M Hirschfield
    University of Toronto and Liver Center, Toronto Western Hospital, Toronto, ON, Canada
    N Engl J Med 360:2544-55. 2009
    ..Twin and family aggregation data suggest that there is a significant genetic predisposition to primary biliary cirrhosis, but the susceptibility loci are unknown...
  65. ncbi request reprint A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue
    Jeremy J Theal
    Department of Medicine, University Health Network, University of Toronto, Toronto, Canada
    Hepatology 41:1305-12. 2005
    ..0% of patients taking ondansetron, versus 13.3% on placebo). In conclusion, ondansetron administration did not confer clinically significant fatigue reduction when compared with placebo in our study population...
  66. ncbi request reprint Indications for interferon/ribavirin therapy in hepatitis C patients: findings from a survey of Canadian hepatologists
    Peter Wang
    Toronto General Hospital, Toronto, Canada
    Can J Gastroenterol 17:183-6. 2003
    ..To survey practising hepatologists about their attitudes and practices regarding interferon and ribavirin combination therapy for hepatitis C (HCV) patients in Canada...
  67. ncbi request reprint Three atypical cases of Wilson disease: assessment of the Leipzig scoring system in making a diagnosis
    Andy Xuan
    Department of Medicine, McMaster University, Hamilton, ON, Canada L8N 3Z5
    J Hepatol 47:428-33. 2007
    ..In 2001, experts from The 8th International Conference on Wilson disease (WD) and Menkes disease in Leipzig, Germany proposed a scoring system that may facilitate diagnosis of WD...
  68. ncbi request reprint Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors
    Mary Pat McAndrews
    Divisions of Psychology, University Health Network, Toronto, Ontario, Canada
    Hepatology 41:801-8. 2005
    ....
  69. doi request reprint Hepatic gene expression and prediction of therapy response in chronic hepatitis C patients
    Nazia Selzner
    Multiorgan Transplant Program, University Health Network, University of Toronto, Toronto General Hospital, 585 University Avenue, Toronto, Ontario, Canada
    J Hepatol 48:708-13. 2008
    ..This article reviews genomics-based predictors of pre-treatment response to antiviral therapy...
  70. ncbi request reprint Sclerosing cholangitis: a focus on secondary causes
    Rupert Abdalian
    Department of Medicine, University Health Network, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada
    Hepatology 44:1063-74. 2006
    ..This article offers a comprehensive review of SSC...
  71. pmc The impact of infection on population health: results of the Ontario burden of infectious diseases study
    Jeffrey C Kwong
    Institute for Clinical Evaluative Sciences, Toronto, Canada
    PLoS ONE 7:e44103. 2012
    ..We sought to quantify the contribution of a wide range of infectious diseases to the overall infectious disease burden in a high-income setting...
  72. pmc Current status of therapy in autoimmune liver disease
    Gideon M Hirschfield
    Toronto Western Hospital, Toronto, Canada
    Therap Adv Gastroenterol 2:11-28. 2009
    ..With better biological understanding, more specific interventions are expected that will benefit all those with autoimmune liver diseases...
  73. ncbi request reprint Benefit of transplantation in primary biliary cirrhosis between 1985-1997
    Jill Tinmouth
    St Michael s Hospital, Toronto, Ontario, Canada
    Transplantation 73:224-7. 2002
    ..This study, using the same model, evaluates a cohort of patients who underwent transplantation in the late 1980s and early 1990s before and after the introduction of therapy with ursodeoxycholic acid (UDCA)...
  74. ncbi request reprint Health-state utilities and quality of life in hepatitis C patients
    Christopher A K Y Chong
    Faculty of Medicine, University of Toronto, Ontario, Canada
    Am J Gastroenterol 98:630-8. 2003
    ..Currently, utilities for hepatitis C virus (HCV)-infected patients have been estimated using expert judgments. The purpose of this study was to elicit HCV utilities directly from patients...
  75. pmc Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports
    Alallam Alallam
    Department of Medicine, University Health Network, University of Toronto, Toronto, Canada
    Can J Gastroenterol 22:505-7. 2008
    ..Plasmapheresis has been successful in controlling pruritus in patients with cholestasis. The use of plasmapheresis to alleviate severe life-threatening pruritus during pregnancy is reported in two patients with PBC...
  76. ncbi request reprint Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin
    Robert H Boone
    Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    Dig Dis Sci 51:1103-12. 2006
    ..In conclusion, women with PBC have strong feelings about HRT, and recruitment for this intervention is difficult. Transdermal estrogen/progestin likely provides protection against bone loss in PBC patients, but may worsen cholestasis...
  77. pmc Poor Perception of Body Weight Category amongst the Overweight and Obese with Chronic Hepatitis C: A Target for Intervention
    Venessa Pattullo
    Department of Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, ON, Canada M5T 2S8
    J Obes 2011:942516. 2011
    ..19) were associated with underestimation of BW category. Targeted interventions are needed to improve body weight perception, thereby enhancing the uptake of health advice on management of excess body weight in CHC...
  78. doi request reprint Does hepatic vein transit time performed with contrast-enhanced ultrasound predict the severity of hepatic fibrosis?
    An Tang
    Department of Medical Imaging, University of Toronto, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
    Ultrasound Med Biol 37:1963-9. 2011
    ..Further work investigating the different interaction of Definity, SonoVue and Levovist with the reticulo-endothelial system may help explain the discrepant results reported here...
  79. ncbi request reprint Primary biliary cirrhosis in a patient with Turner syndrome
    Piotr Milkiewicz
    Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada
    Can J Gastroenterol 19:631-3. 2005
    ..The present case may support the importance of X chromosome genes in the development of genetic predisposition to PBC, and emphasizes the necessity for a systematic study of the prevalence of PBC in patients with Turner syndrome...
  80. ncbi request reprint Federally funded research in hepatology
    Jenny Heathcote
    Department of Medicine University of Toronto Toronto, Ontario, Canada
    Hepatology 39:20. 2004
  81. ncbi request reprint Treatment strategies for autoimmune hepatitis
    Jenny Heathcote
    University of Toronto, Toronto, Canada
    Am J Gastroenterol 101:S630-2. 2006
  82. ncbi request reprint Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C
    Jens Rasenack
    Klinikum der Albert Ludwigs Universität, Freiburg, Germany
    Pharmacoeconomics 21:341-9. 2003
    ..Treatment with peginterferon alpha-2a (40kD) provides an improved sustained response over unmodified interferon alpha-2a...
  83. doi request reprint Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus
    Bart J Veldt
    Erasmus MC University Medical Center, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands
    Hepatology 47:1856-62. 2008
    ..013). Multivariate Cox regression analysis of patients with Ishak 6 cirrhosis showed that diabetes mellitus was independently associated with the development of HCC (hazard ratio, 3.28; 95% CI, 1.35-7.97; P = 0.009)...
  84. ncbi request reprint Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial
    Keith D Lindor
    Division of Gastroenterology and Hepatology, Mayo Clinic W19A, 200 1st Street SW, Rochester, MN 55905, USA
    Hepatology 39:770-8. 2004
    ..In conclusion, 2 years of therapy with UDCA at a dose of 13 to 15 mg/kg/d, although safe and well tolerated, is not better than placebo for patients with NASH...
  85. ncbi request reprint Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data
    Calogero Cammà
    IBIM, Consiglio Nazionale delle Ricerche, Palermo, Italy
    Hepatology 39:333-42. 2004
    ..The beneficial effects of peginterferon on liver histology are closely related to virologic response...
  86. ncbi request reprint Long-term safety of lamivudine treatment in patients with chronic hepatitis B
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, 48109 0362, USA
    Gastroenterology 125:1714-22. 2003
    ..The aim of this analysis was to determine the incidence of hepatitis flares, hepatic decompensation, and liver-disease-related (LDR) serious adverse events (SAE) during long-term lamivudine treatment...
  87. ncbi request reprint Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B
    Marion G Peters
    Division of Gastroenterology, University of California, San Francisco, CA 94143, USA
    Gastroenterology 126:91-101. 2004
    ....
  88. ncbi request reprint Pediatric-onset primary biliary cirrhosis
    Yaser Dahlan
    Division of Gastroenterology, Department of Medicine, University of Alberta, 205 College Plaza, 8215 112 Street, Edmonton, Alberta, Canada T6G 2C7
    Gastroenterology 125:1476-9. 2003
    ..In conclusion, we present 2 liver biopsy-confirmed cases of pediatric-onset AMA-positive PBC. With increased awareness of early-onset PBC, further pediatric cases may be discovered...
  89. ncbi request reprint Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C
    Stefan Zeuzem
    Klinik fur Innere Medizin II, Universitatskliniken des Saarlandes, 66421 Homburg Saar, Germany
    J Hepatol 39:106-11. 2003
    ..Sensitive molecular tests may permit earlier determination of sustained virologic response following the completion of therapy in end-of-treatment responders...
  90. ncbi request reprint Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis
    Renee Eugenie Poupon
    Inserm Unit 370, Faculte de Medecine Necker, 156 rue de Vaugirard, 75730 Paris Cedex 15, France
    J Hepatol 39:12-6. 2003
    ..This study aimed at evaluating the effect of ursodeoxycholic acid (UDCA) treatment on histologic progression in primary biliary cirrhosis (PBC)...
  91. ncbi request reprint Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    N Engl J Med 348:800-7. 2003
    ..Adefovir dipivoxil, a nucleotide analogue, demonstrated clinically significant antiviral activity in patients with chronic hepatitis B in phase 1 and 2 clinical trials...
  92. ncbi request reprint Histological outcome during long-term lamivudine therapy
    Jules L Dienstag
    Gastrointestinal Unit Medical Services, Massachusetts General Hospital, Boston, MA 02114, USA
    Gastroenterology 124:105-17. 2003
    ..One year of lamivudine for chronic hepatitis B results in histologic improvement. We aimed to assess the histological impact of longer-term treatment...
  93. ncbi request reprint Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)
    Samuel S Lee
    Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1
    J Hepatol 37:500-6. 2002
    ..We evaluated the prognostic value of baseline factors and early viral RNA among patients treated with peginterferon alfa-2a (40KD)...
  94. ncbi request reprint Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B
    Robert P Perrillo
    Section of Gastroenterology and Hepatology, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    Hepatology 36:186-94. 2002
    ..Asians and Caucasians had similar rates of response to lamivudine at comparable ALT levels...
  95. ncbi request reprint Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B
    Mario Rizzetto
    Experimental Department of Gastroenterology, San Giovanni Battista Hospital C So Bramante, 88 10126 Turin, Italy
    J Hepatol 42:173-9. 2005
    ..The histological and clinical outcome of lamivudine 100mg/day was assessed in 76 HBeAg-negative chronic hepatitis B patients previously randomised to a double-blind comparison study of lamivudine and placebo...
  96. ncbi request reprint A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients
    Vincent G Bain
    University of Alberta, Liver Unit, Zeidler Ledcor Center, 130 University Campus, Edmonton, Alberta, Canada, T6G 2X8
    J Hepatol 44:671-8. 2006
    ..Recombinant human albumin-interferon alfa (alb-IFN) is a novel 85.7-kD recombinant protein consisting of interferon alfa-2b genetically fused to human serum albumin...
  97. ncbi request reprint Hepatitis B e antigen-positive chronic hepatitis B: natural history and treatment
    Jordan J Feld
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, Maryland, USA
    Semin Liver Dis 26:116-29. 2006
    ..The major challenge for the clinician using these agents is the emergence of antiviral drug resistance. Long-term immune control of viral replication is key to improving patient outcome...
  98. doi request reprint Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a
    Patrick Marcellin
    Service d hépatologie and INSERM CRB3, University of Paris, Hopital Beaujon, Clichy, France
    Liver Int 28:477-85. 2008
    ..Pooled data from five studies of peginterferon alpha-2a in patients with chronic HCV infection (CHC) were compared with two studies of the drug in patients with chronic HBV infection (CHB)...
  99. doi request reprint Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B
    Joseph J Y Sung
    Department of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, People s Republic of China
    J Hepatol 48:728-35. 2008
    ..We aimed to evaluate nucleoside/nucleotide combination therapy in treatment-naïve HBeAg-positive patients with chronic hepatitis B (CHB)...
  100. ncbi request reprint Telbivudine versus lamivudine in patients with chronic hepatitis B
    Ching Lung Lai
    University Department of Medicine, Queen Mary Hospital, Hong Kong, China
    N Engl J Med 357:2576-88. 2007
    ..Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic hepatitis B...
  101. ncbi request reprint Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    N Engl J Med 352:2673-81. 2005
    ..We evaluated the effect of continued therapy as compared with cessation of therapy...